Gilead Sciences Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
October 28, 2020 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.11, $0.16 better than the analyst estimate of $1.95. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.39 billion. Veklury (remdesivir) revenues were $873 million for the third quarter.
The recent acquisition of Immunomedics has effectively transformed Gileads growth story. Building on the foundation of our strong core business, which proved its durability once again this quarter, we have now significant opportunity to drive additional growth at an accelerated pace, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Trodelvy, an approved medicine with... More
